Skip to main content

Table 2 Biochemical and clinical variables measured at baseline and 3-month in subjects according to therapy

From: Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy

 

Empagliflozin group (N = 20)

Control group (N = 15)

Baseline

3-month

Baseline

3-month

Body weight (kg)

89 ± 14

85 ± 13*

80 ± 8

79 ± 10

BMI (kg/m2)

30 ± 4

29 ± 4*

27 ± 3

26 ± 3

Waist (cm)

107 ± 10

105 ± 10*

102 ± 7

100 ± 8

SBP (mmHg)

141 ± 14

136 ± 16

136 ± 23

135 ± 12

DBP (mmHg)

86 ± 11

84 ± 10

78 ± 8

79 ± 9

HR (bpm)

75 ± 11#

69 ± 17

62 ± 6

69 ± 9

FPG (mmol/L)

10.3 ± 3.1

7.9 ± 1.1*

9.7 ± 1.7

8.1 ± 0.9*

HbA1c (%)

8.4 ± 0.7

7.6 ± 0.9*

8.3 ± 0.7

7.7 ± 0.9^

Total-chol (mmol/L)

4.09 ± 0.91

4.12 ± 0.98

4.51 ± 1.40

4.17 ± 1.17*

HDL-chol (mmol/L)

1.11 ± 0.34

1.19 ± 0.31*

0.98 ± 0.31

1.04 ± 0.28

LDL-chol (mmol/L)

2.20 ± 0.78

2.28 ± 0.91

2.31 ± 1.17

2.25 ± 0.88

Triglycerides (mmol/L)

1.76 ± 1.18

1.45 ± 0.67

2.13 ± 1.55

1.88 ± 1.29

  1. Data are expressed as the mean ± SD; t-test for paired data * p < 0.002, ^ p < 0.02 vs baseline; t-test for unpaired data # p = 0.01 vs Control group
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840